Decreased diffusion capacity for carbon monoxide (DLCO) is the most prevalent pulmonary testing abnormality among COVID-19 recoverees. We prospectively followed 51 individuals with impaired DLCO at an average of ∼3 months following COVID-19 and re-examined them at one year. At follow-up, mean DLCO increased from 68.0 % to 72.6 % (p = 0.002); while 33 % of the cohort experienced a clinically significant rise (>10 points) in DLCO, only 29 % normalized their values. While DLCO change did not correlate with symptoms, lack of improvement was more prevalent among individuals with obesity. Regardless of COVID-19 severity, a substantial proportion continued to exhibit DLCO impairment at 1-year.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.idnow.2024.104890 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spa Therapy Efficacy in Mental Health and Sleep Quality Disorders in Patients with a History of COVID-19: A Comparative Study.
Diseases
October 2024
Faculty Applied Healthcare, Deggendorf Institute of Technology-University of Applied Sciences, 94469 Deggendorf, Germany.
The COVID-19 pandemic has left behind mental health issues like anxiety, depression, and sleep disorders among survivors. This study assessed the efficacy of spa therapy in enhancing psychological well-being and sleep quality in individuals with chronic arthro-rheumatic, respiratory, and otorhinolaryngological diseases, including COVID-19 recoverees. Our prospective observational study included 144 Caucasian subjects from three Italian spas who underwent a 2-week spa therapy cycle, involving balneotherapy and/or inhalation treatments.
View Article and Find Full Text PDFOne-year follow-up of COVID-19 recoverees with impaired pulmonary function: A prospective cohort study.
Infect Dis Now
April 2024
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel.
Decreased diffusion capacity for carbon monoxide (DLCO) is the most prevalent pulmonary testing abnormality among COVID-19 recoverees. We prospectively followed 51 individuals with impaired DLCO at an average of ∼3 months following COVID-19 and re-examined them at one year. At follow-up, mean DLCO increased from 68.
View Article and Find Full Text PDFEstimating the economic burden of long-Covid: the additive cost of healthcare utilisation among COVID-19 recoverees in Israel.
BMJ Glob Health
July 2023
Branch of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel.
Introduction: Postacute sequelae resulting from SARS-CoV-2 infections (LONG-COVID) have been reported. The resulting added economic burden from the perspective of healthcare organisations is not clear. Therefore, this study aims to evaluate the additive healthcare costs among COVID-19 recoverees, in a large community-dwelling general population, as incurred by an insurer-provider organisation over time.
View Article and Find Full Text PDFLong COVID sexual dysfunction among both genders: Evaluation of a cohort of COVID-19 recoverees.
Infect Dis Now
October 2023
COVID Recovery Clinic, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel; Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. Electronic address:
Objectives: We aimed to assess Long COVID sexual dysfunction among both sexes.
Patients And Methods: A cross-sectional study at a multidisciplinary COVID clinic. Consecutive patients answered a symptom-based questionnaire, which included sexual dysfunction.
4'-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses.
PLoS Pathog
April 2023
Center for Translational Antiviral Research, Georgia State University Institute for Biomedical Sciences, Atlanta, Georgia, United States of America.
Article Synopsis
- Influenza outbreaks cause significant health issues and economic challenges, highlighting the need for new antiviral treatments to combat both seasonal infections and potential pandemics from avian influenza viruses.
- The study investigates the effectiveness of the nucleoside analog 4'-Fluorouridine (4'-FlU) against various influenza A and B viruses, demonstrating its strong inhibitory action and unique mechanism of targeting the influenza virus polymerase.
- Administering 4'-FlU orally in animal models showed promising results, with rapid cessation of virus spread in ferrets and complete survival in mice after lethal infections, indicating its potential as a candidate for treating seasonal and pandemic influenza.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!